首頁 > 市場調查報告書 > 醫療設備

體外診斷液體活檢

市場調查報告書

商品編碼

1533611

液態切片市場規模、佔有率和成長分析：按產品/服務、按循環生物標記、按技術、按最終用戶、按地區 - 行業預測，2024-2031 年

Liquid Biopsy Market Size, Share, Growth Analysis, By Product & Services, By Circulating Biomarker, By Technology, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年08月05日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球液態切片市場規模約92.8億美元，高於2023年的103.2億美元，預測期間內（2024-2031年）複合年成長率為11.21%，到2031年預計將達到241.4億美元到年底。

由於全球癌症發病率不斷上升以及對更快、侵入性更小的診斷方法的需求不斷成長，液態切片市場正在經歷顯著成長。近年來，非小細胞肺癌已成為美國最常見的肺癌類型。 2010年至2017年間，美國報告了約128萬新發非小細胞肺癌病例。這種高盛行率凸顯了對先進診斷工具（例如液態切片測試）的需求，以有效檢測癌症並幫助制定有針對性的治療計劃。此外，液態切片技術的越來越多的使用反映了向個人化醫療和精準腫瘤學的更廣泛轉變。這些先進的診斷方法比傳統的組織切片檢查具有顯著的優勢，因為它們可以即時監測疾病進展和治療效果。此功能可以實現更及時、更有針對性的介入。由於醫療保健的重點仍然是早期檢測和客製化治療方法，液態切片市場預計將穩步擴張。這一成長是由技術進步、研究活動活性化以及醫療保健專業人員和患者意識的提高所推動的。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

F. Hoffmann-La Roche Ltd（Switzerland）
Thermo Fisher Scientific Inc.（US）
Illumina, Inc.（US）
Guardant Health, Inc.（US）
Biocept, Inc.（US）
Sysmex Corporation（Japan）
Menarini Silicon Biosystems（Italy）
Natera, Inc.（US）
Biocartis Group NV（Belgium）
Personal Genome Diagnostics Inc.（US）
Exosome Diagnostics, Inc.（US）
Bio-Rad Laboratories, Inc.（US）
OncoCyte Corporation（US）
Adaptive Biotechnologies Corporation（US）
Angle plc（United Kingdom）
Epic Sciences, Inc.（US）
NEOGENOMICS LABORATORIES（US）
CellMax Life（US）
MENARINI-SILICON BIOSYSTEMS（Italy）
LUNGLIFE AI, INC.（US）
VORTEX BIOSCIENCES（US）

簡介目錄

Product Code: SQMIG35J2060

Global Liquid Biopsy Market was valued at around 9.28 billion in 2022 and is expected to rise from USD 10.32 billion in 2023 to reach a value of USD 24.14 billion by 2031, at a CAGR of 11.21% during the forecast period (2024-2031).

The liquid biopsy market has experienced significant growth due to the increasing global incidence of cancer and the rising demand for faster, less invasive diagnostic methods. In the United States, non-small-cell lung cancer has emerged as the most prevalent type of lung cancer in recent years. Between 2010 and 2017, there were approximately 1.28 million new cases of non-small-cell lung cancer reported in the US. This high incidence highlights the need for advanced diagnostic tools such as liquid biopsy tests, which can efficiently detect cancer and help develop targeted treatment plans. Moreover, the growing use of liquid biopsy techniques reflects a broader shift towards personalized medicine and precision oncology. These advanced diagnostic methods offer significant advantages over traditional tissue biopsies by enabling real-time monitoring of disease progression and treatment efficacy. This capability allows for more timely and tailored interventions. As the focus of healthcare continues to emphasize early detection and customized treatment approaches, the liquid biopsy market is expected to expand steadily. This growth is fueled by technological advancements, increased research activities, and heightened awareness among both healthcare professionals and patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liquid Biopsy Market Segmental Analysis

The liquid biopsy market is segmented by Product & Services, Circulating Biomarker, Clinical Application, Technology, Application, Sample Type, End-User and Region. Based on Product & Services, the market is segmented into Assay Kits, Instruments, and services. Based on Circulating Biomarker, the market is segmented into Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA, Extracellular Vesicles, and Others. Bases on Clinical Applications, the market is segmented into Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring. Based on Technology, the market is segmented into Multi-Gene Parallel Analysis using NGS, and Single-Gene Analysis using PCR. Based on Application, the market is segmented into Cancer Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others), Non-Cancer Application (Non-Invasive Prenatal Testing, Organ Transplantation, and Infectious Disease Testing). Based on Sample Type, the market is segmented into Blood Samples, Urine Sample, Saliva Sample, and Others. Based on End-User the market is segmented into Hospitals & Clinics, Diagnostic Centers, Reference Laboratories, Academic & Research Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Liquid Biopsy Market

Liquid biopsy techniques offer several advantages over traditional biopsies. As previously noted, they are minimally invasive, resulting in less patient discomfort and making them a more acceptable option for those undergoing diagnostic procedures. Additionally, liquid biopsies are highly effective at capturing tumor heterogeneity, providing a comprehensive view of cancer evolution that facilitates personalized treatment strategies. They also enable real-time monitoring, allowing healthcare providers to track disease progression more accurately and implement timely interventions, which can lead to better patient outcomes. Consequently, the advancements in liquid biopsy methods are preferred by both patients and healthcare providers, driving increased demand and adoption in clinical practice.

Restraints in the Global Liquid Biopsy Market

The liquid biopsy market faces several key challenges, including a lack of standardization and regulatory guidelines. The process of obtaining regulatory approval for liquid biopsy tests is often complex and time-consuming, which can delay the introduction of new products to the market. Additionally, the high cost of liquid biopsy tests and limited reimbursement coverage in certain regions may hinder market growth. Addressing these challenges could involve the development of standardized guidelines and improvements in reimbursement coverage for liquid biopsy tests, which would help mitigate these obstacles and support market expansion.

Market Trends of the Global Liquid Biopsy Market

A significant trend in the liquid biopsy market is the growing use of next-generation sequencing (NGS) technology. NGS facilitates high-throughput sequencing of DNA and RNA, enabling the detection of numerous cancer biomarkers from a single sample. This technology is becoming increasingly favored in liquid biopsy tests due to its ability to provide highly sensitive and specific results. These capabilities enhance early cancer detection and allow for effective monitoring of treatment responses. As the demand for NGS-based liquid biopsy tests continues to rise, it is anticipated to drive substantial growth in the market in the years ahead.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Green Chemical Insights

Technology Analysis
Ecosystem of the Market
Value Chain Analysis
Patent Analysis
Case Study Analysis
Trade Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Liquid Biopsy Market by Products & Services

Market Overview
Assay Kits
Instruments
Services

Liquid Biopsy Market by Circulating Biomarkers

Market Overview
Circulating Tumor Cells
Circulating Tumor DNA
Cell free DNA
Extracellular Vesicles
Others

Liquid Biopsy Market by Clinical Application

Market Overview
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring

Liquid Biopsy Market by Technology

Market Overview
Multi-Gene Parallel Analysis using NGS
Single-Gene Analysis using PCR

Liquid Biopsy Market by Application

Market Overview
Cancer Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Others
Non-Cancer Application
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Infectious Disease Testing

Liquid Biopsy Market by Sample Type

Market Overview
Blood Samples
Urine Sample
Saliva Sample
Others

Liquid Biopsy Market by End-User

Market Overview
Hospitals & Clinics
Diagnostic Centers
Reference Laboratories
Academic & Research Centers
Others

Liquid Biopsy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocept, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Menarini Silicon Biosystems (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personal Genome Diagnostics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exosome Diagnostics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OncoCyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptive Biotechnologies Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Angle plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epic Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NEOGENOMICS LABORATORIES (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CellMax Life (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MENARINI-SILICON BIOSYSTEMS (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LUNGLIFE AI, INC. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
VORTEX BIOSCIENCES (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments